Avenue Therapeutics, Inc. (ATXI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ATXI
- Company Avenue Therapeutics, Inc.
- Price $0.77
- Changes Percentage -21.12
- Change -0.207
- Day Low $0.77
- Day High $0.97
- Year High $13.13
- Year Low $0.77
- Market Cap $1,587,680
- Price Avg 50 EMA (D) $1.45
- Price Avg 200 EMA (D) $2.34
- Exchange NASDAQ
- Volume 169,843
- Average Volume 415,776
- Open $0.94
- Previous Close $0.98
- EPS 24.78
- PE 0.03
- Earnings Announcement 2025-03-17 20:00:00
- Shares Outstanding $2,053,920
Company brief: AVENUE THERAPEUTICS, INC. (ATXI )
- Healthcare
- Biotechnology
- Dr. Alexandra MacLean M.D.
- https://www.avenuetx.com
- US
- N/A
- 06-27-2017
- US05360L3042
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.